sms Pharmaceuticals Limited

Registered & Corporate Office :
Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 30th May, 2025

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Security Code: 532815

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E), Mumbai
- 400 051.
Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Receipt of Establishment Inspection Report (EIR) for Hyderabad manufacturing facility

Ref: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

We wish to inform you that, the Company has received the Establishment Inspection Report from United States Food and Drug Administration (USFDA) for the inspection conducted during March, 2025 at the Company's Active Pharmaceutical Ingredient(API) manufacturing facility located at Bachupally, Hyderabad, Telangana, please find the enclosed Company statement titled "**Establishment Inspection Report (EIR) received for Hyderabad manufacturing facility "**

The above information will also be made available on the website of the Company at www.smspharma.com

This is for your information and records.

Thanking you

Yours Faithfully
For SMS Pharmaceuticals Limited

THIRUMALESH TUMMA
Digitally signed by THIRUMALESH TUMMA
Date: 2025.05.30 19:14:53 +05'30'

Thirumalesh Tumma
Company Secretary

May 30, 2025

Establishment Inspection Report (EIR) received for Hyderabad manufacturing facility

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE:532815) is pleased to announce the successful closure of the recent inspection by the USFDA at its API manufacturing facility at Bachupally, Hyderabad, with the receipt of the Establishment Inspection Report (EIR).

The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483, which was procedural in nature, as previously intimated to the stock exchanges. The company has responded with the corrective action and has received the Establishment Inspection Report (EIR), marking the closure of the audit.

The Hyderabad facility has a 120 KL manufacturing capacity for niche small-volume and high-value molecules. It has multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA and CDSCO.

Commenting on this achievement, Mr. P. Vamsi Krishna, Executive Director, stated*:*
"The successful closure of the recent USFDA inspection is in line with our commitment to quality and compliance across our operations. This outcome further strengthens the trust placed in us by our customers and supports our continued growth in key international markets."

About SMS Pharmaceuticals Limited
Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers. The Company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries.

For any further information, please contact:

Company	Investor relations
SMS Pharmaceuticals Limited Mr. Thirumalesh Tumma Email: complianceofficer@smspharma.com	**Eqsponent** Mr. Aditya Dutta Email: smspharma.IR@eqsponent.com

DISCLAIMER
Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. SMS Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.